SABCS

Orserdu Boosts PFS in ESR1-Mutated Metastatic Breast Cancer Subgroups

December 8th 2023, 8:00pm

Article

Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed.

HER2 Status May Influence Time to Next Treatment Post-Enhertu

December 8th 2023, 2:00pm

Article

Findings were presented at the 2023 San Antonio Breast Cancer Symposium from a study investigating real-world patients who received Enhertu for advanced breast cancer.

Survey Explores Disparities Black Women With TNBC Face

December 7th 2023, 11:00pm

Video

A triple-negative breast cancer survivor discussed disparities she faced when undergoing cancer care.

Dato-DXd Extends PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

December 7th 2023, 10:00pm

Article

Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

Tukysa Plus Kadcyla Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer

December 7th 2023, 8:00pm

Article

The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.

No Racial Difference in Recurrence-Free Survival in HR+, HER2- Breast Cancer

December 7th 2023, 4:03pm

Article

Race demonstrated differences in overall survival outcomes, but not for three-year recurrence-free survival in patients with HR-positive, HER2-negative breast cancer, according to data.

Keytruda Plus Chemo Improves Complete Response Rate in Breast Cancer

December 7th 2023, 2:00pm

Article

The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer.

Phase 2 Evaluating BDC-1001 Plus Perjeta in HER2-Positive Breast Cancer

December 6th 2023, 11:02pm

Article

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.

Truqap Plus Faslodex Boosts Breast Cancer Outcomes, Quality of Life

December 6th 2023, 10:00pm

Article

Patients with HR-positive, HER2-negative breast cancer tended to have longer health-related quality of life and improved outcomes with Truqap plus Faslodex, research showed.

Sentinel Lymph Nodes May Be Detected With AI in Breast Cancer

December 6th 2023, 8:00pm

Article

The use of artificial intelligence to detect sentinel lymph nodes in patients with breast cancer may be able to save time and reduce costs as compared with immunohistochemistry.